GCTK

Company Overview — What Does Glucotrack, Inc. Do?

GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel. Glucotrack, Inc. (GCTK) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Paul V. Goode and employs approximately 5 people. With a market capitalization of $809,023, GCTK is one of the notable companies in the Healthcare sector.

Glucotrack, Inc. (GCTK) Stock Rating — Avoid (April 2026)

As of April 2026, Glucotrack, Inc. receives a Avoid rating with a composite score of 18.2/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.GCTK ranks #4,266 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Glucotrack, Inc. ranks #771 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

GCTK Stock Price and 52-Week Range

Glucotrack, Inc. (GCTK) currently trades at $0.67. The stock gained $0.01 (2.3%) in the most recent trading session. The 52-week high for GCTK is $15.90, which means the stock is currently trading -95.8% from its annual peak. The 52-week low is $0.09, putting the stock 617.4% above its annual trough. Recent trading volume was 117K shares, suggesting relatively thin trading activity.

Is GCTK Overvalued or Undervalued? — Valuation Analysis

Glucotrack, Inc. (GCTK) carries a value factor score of 6/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 0.02x, compared to the Healthcare sector average of 23.63x — a discount of 100%. The price-to-book ratio stands at 0.47x, versus the sector average of 2.75x.

At current multiples, Glucotrack, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Glucotrack, Inc. Profitability — ROE, Margins, and Quality Score

Glucotrack, Inc. (GCTK) earns a quality factor score of 8/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -737.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -266.0% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

GCTK Debt, Balance Sheet, and Financial Health

Glucotrack, Inc. has a debt-to-equity ratio of 177.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.61x, suggesting adequate working capital coverage. Total debt on the balance sheet is $3M. Cash and equivalents stand at $8M.

GCTK has a beta of 16.99, meaning it is more volatile than the broader market — a $10,000 investment in GCTK would be expected to move 1598.8% more than the S&P 500 on any given day. The stability factor score for Glucotrack, Inc. is 2/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Glucotrack, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Glucotrack, Inc. reported revenue of $0 and earnings per share (EPS) of $31.22. Net income for the quarter was $-21M. Operating income came in at $-16M.

In FY 2025, Glucotrack, Inc. reported revenue of $0 and earnings per share (EPS) of $31.22. Net income for the quarter was $-19M. Operating income came in at $-16M.

In Q3 2025, Glucotrack, Inc. reported revenue of $0 and earnings per share (EPS) of $4.64. Net income for the quarter was $-4M. Operating income came in at $-4M.

In Q2 2025, Glucotrack, Inc. reported revenue of $0 and earnings per share (EPS) of $9.62. Net income for the quarter was $-5M. Operating income came in at $-5M.

Over the past 8 quarters, Glucotrack, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing GCTK stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

GCTK Dividend Yield and Income Analysis

Glucotrack, Inc. (GCTK) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

GCTK Momentum and Technical Analysis Profile

Glucotrack, Inc. (GCTK) has a momentum factor score of 45/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 10/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

GCTK vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Glucotrack, Inc. (GCTK) ranks #771 out of 838 stocks based on the Blank Capital composite score. This places GCTK in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing GCTK against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full GCTK vs S&P 500 (SPY) comparison to assess how Glucotrack, Inc. stacks up against the broader market across all factor dimensions.

GCTK Next Earnings Date

No upcoming earnings date has been announced for Glucotrack, Inc. (GCTK) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy GCTK? — Investment Thesis Summary

The quantitative profile for Glucotrack, Inc. suggests caution. The quality score of 8/100 flags below-average profitability. The value score of 6/100 indicates premium valuation. High volatility (stability score 2/100) increases portfolio risk.

In summary, Glucotrack, Inc. (GCTK) earns a Avoid rating with a composite score of 18.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on GCTK stock.

Related Resources for GCTK Investors

Explore more research and tools: GCTK vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare GCTK head-to-head with peers: GCTK vs AZN, GCTK vs SLGL, GCTK vs VMD.